Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. - Wikidata - awgldk - TriplyDB

Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9.

Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9.

http://www.wikidata.org/entity/Q33990888

about

Menopausal symptoms in young survivors of breast cancer: a growing problem without an ideal solution κ Agonists as a novel therapy for menopausal hot flashes.A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7.Sexual function in women on estradiol or venlafaxine for hot flushes: a randomized controlled trial.Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause.Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions.Pilot evaluation of a stellate ganglion block for the treatment of hot flashes.Mindfulness training for coping with hot flashes: results of a randomized trial.A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients Escitalopram treatment of menopausal hot flashes.Hot flashes: a review of pathophysiology and treatment modalities.North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes.Is complementary and alternative therapy effective for women in the climacteric period?Use and perceived efficacy of complementary and alternative medicines after discontinuation of hormone therapy: a nested United Kingdom Collaborative Trial of Ovarian Cancer Screening cohort study.Androgen deprivation therapy-associated vasomotor symptoms Sexual function in nondepressed women using escitalopram for vasomotor symptoms: a randomized controlled trial Effect of escitalopram on hot flash interference: a randomized, controlled trial Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine.Risk factors, pathophysiology, and treatment of hot flashes in cancer.Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions Sternal skin conductance: a reasonable surrogate for hot flash measurement?Phase II evaluation of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes.How well do different measurement modalities estimate the number of vasomotor symptoms? Findings from the Study of Women's Health Across the Nation FLASHES Study.Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.Nonhormonal management of hot flashes for women on risk reduction therapy.Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: what needs to be known for practice.Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations.Hot flushes in women with breast cancer: state of the art and future perspectives.Validity, cut-points, and minimally important differences for two hot flash-related daily interference scales.Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors.Management of Potential Long-Term Toxicities in Breast Cancer Patients.Differences in clinician understanding and management of early menopause after breast cancer.Efficacy of a biobehavioral intervention for hot flashes: a randomized controlled pilot study.Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up.

P2860

Q27025094-8B9E0A1A-B084-47FD-BB25-6E47C42F0A32 Q30355071-40E64DEB-B317-48F1-9258-D1C459398544 Q33451759-7A1C8140-B3B1-47B8-8EBC-22286A0C7465 Q33964099-EB6FA6D1-3B1E-45B3-B3B1-2FC1FBF1830C Q34243328-DC45355F-B09D-45D2-BBA2-179C4754FBFB Q34272132-3C884CE1-4B07-4098-9AEF-B635999C58B4 Q35022143-86A2BDED-997C-4E85-B003-A4483C27507D Q35068756-97C830DC-698C-4F89-9E84-C5A04C31B717 Q35092002-8CD1404A-2184-4A1B-BD58-042DA03B993F Q35234675-F02DFB56-B547-45CB-8B3A-DB47F7E60224 Q35599841-31BFE24E-00B0-4645-BADD-0921B91E303B Q35639908-33058F1F-FA9C-4E40-ADF4-5054BE2E9EFA Q35675788-6B02943D-A14E-4900-BA2D-4C2D631D68CA Q35751415-4952D15B-220A-447F-A207-2FC1ABF832A8 Q35917204-304DFFD4-78F1-4C34-B272-992548AFC5BB Q35936499-330EB7CE-AD14-4730-8DBF-491C14A9E5DD Q36007860-F13E15DA-C217-406A-9E50-1C29E50D9BB3 Q36055178-D7CFFD15-AF26-4497-9C23-FAB7061EAB37 Q36136356-0CDC732B-1BA1-4FE1-82FB-B3A73D56394B Q36807455-AFB37C58-35BB-4F94-A2F1-04178FFD00F3 Q36818466-79C37977-002E-4972-8BC3-AA0DE49800D9 Q37048734-EBF2C0BF-40A3-4AB1-A0B4-C82190DE94A5 Q37152016-C5FF4155-610C-4581-83C4-7687157EF785 Q37266107-A129E637-6D49-4F67-8CBD-4F0E7FF39730 Q37284439-A46F71C6-BBA9-4126-898A-F28747004B34 Q37579591-B66ED93D-C143-44F4-A241-3F48154A31F2 Q37965541-893A9D69-5494-4F0A-BE58-17C6FDE0F6C2 Q38084117-550BA36B-B15F-41B5-800B-7401A7EDFBDB Q38169220-67AAF962-DF86-496B-BBE9-EF17BB9C48C4 Q38683235-4BB60072-5E11-4B88-84DC-4CC09BBDE19B Q39175842-77E97D8F-F12E-44F6-9C60-3C506181B172 Q39305824-1F9F4D38-A6B3-4BD5-A092-217E726100EF Q44835501-4A74B220-0468-4513-9C61-EF325AF0B995 Q47948024-B49DCF0C-BCC5-4C3E-B2C8-050F6226D093 Q48218348-6036FDA7-C89E-4BD1-8249-5F3158591053

P2860

Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9.

http://www.wikidata.org/entity/Q33990888

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase III, placebo-controlled ...... ot flashes: NCCTG trial N05C9.

@ast

Phase III, placebo-controlled ...... ot flashes: NCCTG trial N05C9.

@en

type

label

Phase III, placebo-controlled ...... ot flashes: NCCTG trial N05C9.

@ast

Phase III, placebo-controlled ...... ot flashes: NCCTG trial N05C9.

@en

prefLabel

Phase III, placebo-controlled ...... ot flashes: NCCTG trial N05C9.

@ast

Phase III, placebo-controlled ...... ot flashes: NCCTG trial N05C9.

@en

P1433

Q33990888-E552000A-52E3-4119-8634-FEFE00E9B166

P1476

Q33990888-6DAB3E31-2E20-4973-8F5E-5BE8E146753A

P2093

Q33990888-3BCBCE87-243E-4008-B9DC-D40E7BBEC9E0

Q33990888-5332A26C-5FAA-4933-8475-6C16930C8DE9

Q33990888-85818236-125A-4FA1-B428-F0D0C1F33185

Q33990888-9BF338DC-DCE8-4865-9427-128212E1219A

Q33990888-BDC21087-009E-47F7-AE0D-DB88B57437B0

Q33990888-CA352C97-C03F-48F3-A5CD-FDE0403FE432

Q33990888-DC9C7E1C-901E-48F0-8461-6D85B7A3428F

Q33990888-E076EC01-6FF3-466A-8128-79602F890FD8

Q33990888-E1AF03CC-08DC-418B-B73F-0BC34A119DB7

Q33990888-F0D2C1F2-8DFE-4461-B305-66B8A3C3568B

P2860

Q33990888-050A7A6C-DB4C-4950-91DA-6FEF44FBD4E5

Q33990888-109B641F-8C47-493C-82DE-977FE822D7CE

Q33990888-112D117A-661F-458E-AFB3-E1DE0AE5E27F

Q33990888-2607E102-BCC4-447F-8671-E4E39C89C1FE

Q33990888-2EEF87E9-C442-4ACF-89D8-7EECD740A076

Q33990888-3949DDAF-374F-4F04-AD09-F5020067172B

Q33990888-3C1C2713-5ACC-44C5-8DE3-512D8A8754D3

Q33990888-609CB42B-2F45-4EEA-8A64-77F31035EC94

Q33990888-60A4D90E-0A30-480C-A40C-47E9756C5C4A

Q33990888-6FA86368-34B4-4FD5-88E9-7DBECE80EA6F

P304

Q33990888-A67C3283-18D6-430D-945E-6993C04DA510

P31

Q33990888-08C205F8-A3F5-4287-91C6-E32DFE13B15D

P356

Q33990888-6222F5E4-5296-421F-BF67-13268E663031

P407

Q33990888-62EB9DAB-6FF1-472D-BA2C-450C5B7783E9

P433

Q33990888-592C7FDC-2B4B-4CA0-B98D-566CD21E29F0

P478

Q33990888-2FA34600-0EEE-491F-8E2C-8FD6998B5D94

P577

Q33990888-1D839A82-85FE-4E9B-AAD6-C668E576F83F

P5875

Q33990888-98CB808C-0F30-4F6A-8AD1-1CAF0F8179BB

P698

Q33990888-40778F04-A1A6-496C-BA29-E448C15FD701

P921

Q33990888-0AECF2C2-9FBC-4C89-BEDA-4CFF9566208A

Q33990888-B749220B-983E-41AD-A791-0A0CC60C40E6

P932

Q33990888-AF092CA2-51AC-41EF-BF94-086B6B7101DD

P356

JCO.2009.26.6379

P1433

Journal of Clinical Oncology

P1476

Phase III, placebo-controlled ...... ot flashes: NCCTG trial N05C9.

@en

P2093

Allen N Stawis

http://www.w3.org/2001/XMLSchema#string

Beth I LaVasseur

http://www.w3.org/2001/XMLSchema#string

Brent Diekmann

http://www.w3.org/2001/XMLSchema#string

Charles L Loprinzi

http://www.w3.org/2001/XMLSchema#string

David B Johnson

http://www.w3.org/2001/XMLSchema#string

Debra L Barton

http://www.w3.org/2001/XMLSchema#string

Jeff A Sloan

http://www.w3.org/2001/XMLSchema#string

Kathleen A Flynn

http://www.w3.org/2001/XMLSchema#string

Missy Dyar

http://www.w3.org/2001/XMLSchema#string

Pamela J Atherton

http://www.w3.org/2001/XMLSchema#string

P2860

Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1

Pathophysiology and treatment of hot flashes.

Acute consequences of the menopausal transition: the rise of common menopausal symptoms.

Centrally active nonhormonal hot flash therapies.

Bio-psycho-socio-cultural perspectives on menopause.

Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.

Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid.

Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis.

Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis.

P304

3278-3283

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.26.6379

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44626421

http://www.w3.org/2001/XMLSchema#string

P698

20498389

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

2903326

http://www.w3.org/2001/XMLSchema#string